@article{3023009,
    title = "Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans",
    author = "Samonis, G. and Thomakos, N. and Liakakos, T. and Macheras, A. and Mandrekas, D. and Kanavaki, S. and Bafaloukos, D. and Maraki, S.",
    journal = "Antiviral Chemistry and Chemotherapy",
    year = "2001",
    volume = "47",
    number = "5",
    pages = "350-353",
    doi = "10.1159/000048542",
    keywords = "antibiotic agent;  cefepime;  meropenem, adult;  aged;  antibiotic therapy;  article;  bacterial colonization;  Candida albicans;  candidiasis;  clinical article;  colony forming unit;  controlled study;  drug effect;  feces culture;  female;  human;  infection risk;  intestine infection;  male;  monotherapy;  priority journal, Adult;  Aged;  Candida albicans;  Candidiasis;  Cephalosporins;  Digestive System;  Female;  Humans;  Male;  Middle Aged;  Population Dynamics;  Postoperative Complications;  Risk Factors;  Thienamycins",
    abstract = "Background: The study evaluated the effects of cefepime and meropenem on the gastrointestinal (GI) colonization of surgical patients by Candida albicans. Patients and Methods: Twenty adult surgical patients who received intravenously either of these antibiotics as monotherapy for the treatment of an existing infection were studied prospectively. Ten patients received cefepime (2.0 g twice a day), and another ten meropenem (1.0 g every 8 h) for 7 days. Quantitative stool cultures for C. albicans were performed immediately before, at the end, and 1 week after the end of antibiotic treatment. Results: Both antibiotics increased the GI colonization of patients by Candida. Meropenem caused a higher increase (2.0 log 10 CFU/g of stool) as compared to cefepime (1.7 log 10 CFU/g of stool). However, these increases were statistically not significant. Conclusion: Cefepime and meropenem when given to sensitive patients do not increase significantly the risk of Candida infection originating in the GI tract. Copyright © 2001 S. Karger AG, Basel."
}